Johnson & Johnson is launching their corona vaccine in Europe. Nordya believes that this has also delayed Norway’s next interest rate hike.
Johnson & Johnson has decided
The company wrote in a press release on its website that after consultations with health authorities, it delayed the promotion of the corona vaccine in Europe.
The U.S. Drug Administration has set the use of the vaccine Rest in the U.S. At the same time, several cases of blood clots in women between the ages of 18 and 48 are being investigated.
-Kjetil Olsen, chief economist at Nordea, told E24 that this will be of great significance in terms of time.
He believes that postponing vaccination will also postpone the first interest rate hike by the Norges Bank.
If the Johnson & Johnson vaccine is not used at all, it will mean that the economy will recover 2-3 months later than previously predicted.
-Depending on when you get enough vaccines, the entire recovery is critical. Olsen said that if the vaccination is delayed for 2-3 months, it also means that the time economy will recover in 2-3 months.
At the press conference of the health authorities on Tuesday afternoon, Line Vold from NIPH pointed out that the vaccination of the Norwegian population may be Delayed by 8-12 weeksIf Norway does not use Johnson & Johnson vaccine and AstraZeneca vaccine.
Olsen pointed out that Norges Bank will emphasize the progress of vaccination when providing forecasts.
-Before any operation, Norges Bank will see “signs of normalization”. The chief economist said that these signs are now appearing.
I Monetary Policy Report In March, Norges Bank wrote that the key policy rate is likely to increase “during the second half of this year.”
Before Johnson & Johnson had problems, Nuodia believed that the first rate hike was as early as September. If the vaccine is not used, Olsen believes that the first rate hike will take place in December.
-Currently, the situation shows that the first rate hike was more in December than in September.Olsen said that I began to be skeptical of Johnson & Johnson and AstraZeneca.
Both vaccines use the same type of vaccine technology, and both have experienced rare associations with blood clots.